Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2009-03-12 Board/Management Inform…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated March 9, 2009. The content focuses on the resignation of a senior officer (Vice President, Finance and CFO) and the appointment of a new Principal Financial and Accounting Officer. This is a clear announcement of changes in the company's senior management. There are no financial statements or detailed financial data, so it is not an annual or interim report. The document is not a proxy statement, earnings release, or any other type of report. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2905 characters, which is consistent with a typical 8-K filing for management changes.
2009-03-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing its second quarter fiscal year 2009 results. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis itself. The length is 2623 characters, which is relatively short and consistent with a current report or announcement rather than a full financial report. The document is primarily an announcement of earnings results rather than the earnings release itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report filing that includes a press release but does not contain the full earnings release or detailed financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-02-12 English
FORM 10-Q
Interim / Quarterly Report H1 2009
2009-02-11 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated January 30, 2009. The key content is the appointment of Dr. Paul Ashton as President and CEO, which is a change in senior management. There are no financial statements or detailed financial data presented. The document includes a press release as an exhibit announcing the appointment. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length is 3354 characters, which is relatively short and consistent with a management change announcement rather than a full financial report or earnings release.
2009-02-04 English
FORM4
Director's Dealing
2008-11-20 English
FORM 4
Director's Dealing
2008-11-20 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.